The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $122.19 in the prior trading day, Encompass Health Corp (NYSE: EHC) closed at $121.94, down -0.20%. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 0.76 million shares were traded. EHC stock price reached its highest trading level at $122.325 during the session, while it also had its lowest trading level at $121.11.
Ratios:
Our goal is to gain a better understanding of EHC by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 71.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.97. For the most recent quarter (mrq), Quick Ratio is recorded 1.06 and its Current Ratio is at 1.06. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 1.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, KeyBanc Capital Markets on October 11, 2024, initiated with a Overweight rating and assigned the stock a target price of $115.
On July 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $100.
On March 06, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $95.Barclays initiated its Overweight rating on March 06, 2024, with a $95 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 20 ’25 when Tarr Mark J sold 118,384 shares for $121.53 per share. The transaction valued at 14,387,152 led to the insider holds 527,070 shares of the business.
Mark Tarr bought 118,384 shares of EHC for $14,383,656 on May 20 ’25. On May 06 ’25, another insider, Charbonneau Elissa Joy, who serves as the Chief Medical Officer of the company, sold 4,279 shares for $116.61 each. As a result, the insider received 498,974 and left with 11,958 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EHC now has a Market Capitalization of 12282285056 and an Enterprise Value of 15676963840. As of this moment, Encompass’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.84, and their Forward P/E ratio for the next fiscal year is 21.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.94. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.17 while its Price-to-Book (P/B) ratio in mrq is 5.40. Its current Enterprise Value per Revenue stands at 2.765 whereas that against EBITDA is 12.219.
Stock Price History:
The Beta on a monthly basis for EHC is 0.93, which has changed by 0.3319497 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, EHC has reached a high of $124.67, while it has fallen to a 52-week low of $87.85. The 50-Day Moving Average of the stock is 4.67%, while the 200-Day Moving Average is calculated to be 14.30%.
Shares Statistics:
The stock has traded on average 850.72K shares per day over the past 3-months and 685040 shares per day over the last 10 days, according to various share statistics. A total of 100.90M shares are outstanding, with a floating share count of 99.21M. Insiders hold about 1.51% of the company’s shares, while institutions hold 94.57% stake in the company. Shares short for EHC as of 1755216000 were 1028940 with a Short Ratio of 1.14, compared to 1752537600 on 988914. Therefore, it implies a Short% of Shares Outstanding of 1028940 and a Short% of Float of 1.15.
Dividends & Splits
In the trailing 12 months, EHC’s forward annual dividend rate was 0.68, compared to 0.68 this year. Against a Trailing Annual Dividend Yield of 0.0055651036The stock’s 5-year Average Dividend Yield is 1.22. The current Payout Ratio is 14.35% for EHC, which recently paid a dividend on 2025-07-01 with an ex-dividend date of 2025-10-01. Stock splits for the company last occurred on 2022-07-01 when the company split stock in a 1257:1000 ratio.
Earnings Estimates
As of right now, 13.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.3, with high estimates of $1.35 and low estimates of $1.24.
Analysts are recommending an EPS of between $5.32 and $5.24 for the fiscal current year, implying an average EPS of $5.28. EPS for the following year is $5.78, with 13.0 analysts recommending between $6.2 and $5.55.
Revenue Estimates
12 analysts predict $1.48B in revenue for the current quarter. It ranges from a high estimate of $1.5B to a low estimate of $1.47B. As of the current estimate, Encompass Health Corp’s year-ago sales were $1.35BFor the next quarter, 12 analysts are estimating revenue of $1.54B. There is a high estimate of $1.56B for the next quarter, whereas the lowest estimate is $1.53B.
A total of 12 analysts have provided revenue estimates for EHC’s current fiscal year. The highest revenue estimate was $5.96B, while the lowest revenue estimate was $5.89B, resulting in an average revenue estimate of $5.93B. In the same quarter a year ago, actual revenue was $5.37BBased on 12 analysts’ estimates, the company’s revenue will be $6.45B in the next fiscal year. The high estimate is $6.5B and the low estimate is $6.39B.
